Antazoline: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: October 31, 2025🚩 Report this page

Antazoline

Active ingredient · 2 therapeutic classes

GB MHRA

Drug class: Other Antihistamines For Systemic Use
Availability: See label
Markets covered: 1
Products on record: 1

R06AXOther Antihistamines For Systemic Use R01ACAntiallergic Agents, Excl. Corticosteroids

Overview

Antazoline is an active pharmaceutical ingredient in the Other Antihistamines For Systemic Use group (R06AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	October 31, 2025

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised October 31, 2025[1]

For the temporary relief of redness and itching of the eye due to seasonal and perennial allergies such as hay fever or house dust allergy.

How to take

Sources & citations

[1]MHRA (UK) · PL201620016 · revised October 31, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised October 31, 2025[1]

Otrivine-Antistin is generally well tolerated, but the following effects have been reported. Adverse events are categorised by frequency as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000), not known (frequency cannot be estimated from the available data).
g. rash, oedema, pruritus) have been reported post- marketing. Although administered via the topical route, systematic side effects may occur in sensitive patients: - tachycardia (especially in small children), palpitations, arrhythmia, hypertension, - occipital headache, - nausea, paleness and sweating Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

GBOfficial regulatory label· Warnings and precautions· revised October 31, 2025[1]

Like other topically applied ophthalmic drugs, Otrivine-Antistin may be absorbed systemically and occasionally cause systemic sympathomimetic effects such as hypertension, nervousness, nausea, dizziness, headache, insomnia, palpitations, tachycardia, and arrhythmia.
Otrivine-Antistin should be used with caution in elderly patients with severe cardiovascular disease, including arrhythmia, poorly controlled hypertension or diabetes. Use with caution in the presence of hypertension, cardiac irregularities, hyperthyroidism, diabetes mellitus or phaeochromocytomas.
Patients with long QT syndrome treated with xylometazoline may be at increased risk of serious ventricular arrhythmias. Otrivine-Antistin should also be used with caution in patients with conditions causing urinary retention such as prostatic hypertrophy and should also be used in caution in patients who are currently receiving other sympathomimetic drugs.
Not suitable for patients suffering from dry eyes without first seeking medical advice. Rebound hyperaemia may follow prolonged frequent use. Otrivine- Antistin should not be used without supervision over a long period of time. If the symptoms do not improve after 2 days, medical advice should be sought to rule out the possibility of a bacterial infection.
Inflammation arising from infection should receive appropriate anti-bacterial therapy. Eye drops are not for injection. They should never be injected subconjunctivally, nor should they be directly introduced into the anterior chamber of the eye.
1 mg/ml. Benzalkonium chloride may cause eye irritation, especially with dry eyes or disorders of the cornea. Patients should be instructed to talk to a doctor if they feel abnormal eye sensation, stinging or pain in the eye after using this medicine.
This medicine contains boric acid. This medicine should not be given to a child younger than 2 years without medical advice, as it contains boron and may impair fertility in the future.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations